Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ: NAMSW )

9.950 -0.470 (-4.51%)
Streaming Delayed Price Updated: 3:43 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NewAmsterdam Pharma Company N.V. - Warrant

< Previous 1 2 Next >
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET 
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.